Immune and cytokine landscape differs between cytopenic and proliferative phenotypes in primary myelofibrosis
Therapeutic Advances in Hematology · 2026-07 · 17
DOI: 10.1177/20406207261474950 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 18.08.2026. Verfasst von Sze-Hwei Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Clinical Medicine, National Taiwan University, Taipei, Taiwan. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Science and Technology.
Abstract (Originalsprache)
Background
Cytopenia represents a distinct clinical phenotype in primary myelofibrosis (PMF), often associated with advanced disease and poor prognosis. We propose that while a common driver mutation initiates the disease, the clinical phenotype of PMF is shaped by inter-individual variability in downstream inflammatory responses, contributing to the observed heterogeneity in disease presentation.
Objectives
To characterize inflammatory and immune signatures distinguishing cytopenic from proliferative phenotypes of PMF.
Design
Retrospective, single-center observational study analyzing clinical, molecular, transcriptomic, and cytokine data from patients with pathologically confirmed PMF.
Methods
We analyzed a cohort of 140 patients with PMF, stratified into cytopenic and proliferative phenotypes based on abnormalities in at least one peripheral blood lineage. Bone marrow transcriptomic profiling was performed using the NanoString nCounter PanCancer Immune Panel. Cytokine levels were measured by MILLIPLEX® bead-based multiplex assay, and phosphorylated NFκB p65 expression was evaluated by immunohistochemistry.
Results
Compared with the proliferative phenotype, cytopenic PMF showed more advanced disease features, including higher blast counts (P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate Institute of Clinical Medicine, National Taiwan University, Taipei, Taiwan.
- Division of Cellular Therapy, Department of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
- Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Pathology, National Taiwan University Cancer Center, Taipei, Taiwan.
- Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
ORCID-Profile: Sze-Hwei Lee, Yu-Sung Chang, Chang-Tsu Yuan
Förderung
- Ministry of Science and Technology
Zitieren
APA
Lee, S. H., Wang, Y. H., Chang, Y. S., Wei, C. H., Yuan, C. T., Hou, H. A., Chou, W. C., Tien, H. F., & Lin, C. C. (2026). Immune and cytokine landscape differs between cytopenic and proliferative phenotypes in primary myelofibrosis. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261474950
Vancouver
Lee SH, Wang YH, Chang YS, Wei CH, Yuan CT, Hou HA, et al. Immune and cytokine landscape differs between cytopenic and proliferative phenotypes in primary myelofibrosis. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261474950
BibTeX
@article{Lee2026,
author = {Lee, Sze-Hwei and Wang, Yu-Hung and Chang, Yu-Sung and Wei, Chao-Hung and Yuan, Chang-Tsu and Hou, Hsin-An and Chou, Wen-Chien and Tien, Hwei-Fang and Lin, Chien-Chin},
title = {Immune and cytokine landscape differs between cytopenic and proliferative phenotypes in primary myelofibrosis},
journal = {Therapeutic Advances in Hematology},
year = {2026},
volume = {17},
doi = {10.1177/20406207261474950}
}
EUVIMED